Company Research Report: Travere Therapeutics
Company Overview
Name and Mission
- Company Name: Travere Therapeutics
- Mission: To identify, develop, and deliver life-changing therapies to people living with rare diseases, particularly those with rare kidney disease.
Foundation and Founders
- No information is available regarding the founding year and founders of the company.
Key People
- Eric Dube, Ph.D.: President & Chief Executive Officer
- Chris Cline, CFA: Chief Financial Officer
- Angela Giannantonio: Senior Vice President, Human Resources
- Peter Heerma: Chief Commercial Officer
- Jula Inrig, M.D.: Chief Medical Officer
- Casey Logan: Chief Business Officer
- Elizabeth Reed, J.D.: Senior Vice President, General Counsel, Corporate Secretary
- William Rote, Ph.D.: Senior Vice President, Research & Development
- Charlotte Smith: Senior Vice President, Public Affairs
Headquarters
- No information is available on the precise location of the company headquarters.
Number of Employees
- Travere Therapeutics has 375+ employees.
Revenue
- No information is available regarding the company's revenue.
Areas of Expertise
- Known for developing therapies for rare diseases, specifically targeting rare kidney and metabolic disorders.
Products
Products Offered
- Filspari® (sparsentan): A therapy for IgA nephropathy.
- Thiola® and Thiola EC®: Registered trademarks products known for treating cystinuria.
- No additional specific product information is available.
Product Descriptions and Features
- Filspari® (sparsentan): Approved by the FDA to slow kidney function decline in adults with primary IgA nephropathy.
- Features: Non-immunosuppressive, aimed to preserve kidney function.
- Thiola® and Thiola EC®: Primarily used to manage cystinuria.
- Features: Designed to reduce cystine levels in the urine to prevent stone formation.
Recent Developments
Recent Developments in the Company
- Full U.S. FDA approval of a treatment for IgA nephropathy (IgAN).
- Significant financial moves including completion of a public offering of common stock and associated inducement grants.
New Products Launched
- No information is available on additional new product launches besides Filspari®.
New Features Added to Products
- No information is available on any new features added to existing products.
Partnerships
- Exclusive commercial rights for Filspari® granted to CSL Vifor in Europe, Australia, and New Zealand, and to Renalys Pharma for Japan, South Korea, Taiwan, and Southeast Asian nations.
Advancements and Other Initiatives
- Engaged in late-stage clinical development for focal segmental glomerulosclerosis (FSGS), with a pause in the HARMONY Study for commercial manufacturing scale-up.
- Supporting whole genome sequencing (WGS) initiatives in newborn screening to quicken rare disease diagnosis.
- Focus on diversity, equity, and inclusion through initiatives like the Rare Disease Diversity Coalition and a Diversity Inclusion Advocacy Fellowship with the EveryLife Foundation.
- Active participation in policy advocacy and patient support including telehealth initiatives and compassionate use programs.
Conclusion
Travere Therapeutics remains focused on advancing its therapeutic pipeline, providing support for rare disease patients, and promoting healthcare equity and innovation. Its recent FDA approval of Filspari® signals a significant milestone in its commitment to developing impactful rare disease treatments.
